RCM
CARM

Rotella Capital Management’s Carisma Therapeutics CARM Stock Holding History

Rotella Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,622
Closed -$338K – 49
2015
Q4 		$338K Sell
5,622
-3,925
-41% -$223K 0.3% 182
2015
Q3 		$460K Buy
+9,547
New +$588K 0.15% 235

Other funds holding CARM

FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
FVFI
Flagship Ventures Fund IV Cambridge, Massachusetts $382M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Rotella Capital Management's CARM Position: Q1 2016 in Review

Rotella Capital Management sold out of Carisma Therapeutics (CARM) in Q1 2016, closing a stake of 5,622 shares — an estimated $338K sold.

Rotella Capital Management first reported a position in CARM in Q3 2015 and held it in 2 quarters. The position peaked at $460K in Q3 2015. 23 funds tracked by Wall St. Rank hold CARM as of Q1 2016.

  • Rotella Capital Management reported no remaining Carisma Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 5,622 Carisma Therapeutics shares in Q1 2016, an estimated $338K.
  • Rotella Capital Management first reported a position in Carisma Therapeutics in Q3 2015 and held it in 2 quarters.
  • Rotella Capital Management's Carisma Therapeutics position peaked at $460K in Q3 2015.
  • 23 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.